Skip to main content

Table 3 A570 values of different treatments when adding drug and virus simultaneously (n = 6)

From: Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes

GP Concentration (μg.mL− 1)

A 570

Hepatocyte protection rate rate(%)

pGP Concentration (μg.mL− 1)

A 570

Hepatocyte protection rate rate(%)

100

0.515 ± 0.004a

108.74

25

0.509 ± 0.003a

99.26

50

0.425 ± 0.008b

59.56

12.5

0.487 ± 0.005a

82.96

25

0.374 ± 0.008c

31.69

6.25

0.421 ± 0.007b

34.07

12.5

0.353 ± 0.008d

20.22

3.125

0.422 ± 0.010b

34.81

6.25

0.336 ± 0.008de

10.93

1.563

0.401 ± 0.007bc

19.26

3.125

0.322 ± 0.007e

3.28

0.781

0.396 ± 0.007bc

15.56

0(VC)

0.316 ± 0.006e

 

0(VC)

0.375 ± 0.005c

 

0(CC)

0.499 ± 0.005a

 

0(CC)

0.510 ± 0.005a

 
  1. a-eData in same column without same superscript (a–e) differ significantly(P < 0.05)
  2. GP Gypenoside, pGP phosphorylated gypenoside, VC virus control, CC cell control